Context Therapeutics Statistics
Total Valuation
CNTX has a market cap or net worth of $56.51 million. The enterprise value is -$35.45 million.
Important Dates
The last earnings date was Thursday, March 20, 2025, after market close.
| Earnings Date | Mar 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
CNTX has 89.70 million shares outstanding. The number of shares has increased by 265.88% in one year.
| Current Share Class | 89.70M |
| Shares Outstanding | 89.70M |
| Shares Change (YoY) | +265.88% |
| Shares Change (QoQ) | +1.80% |
| Owned by Insiders (%) | 1.21% |
| Owned by Institutions (%) | 27.85% |
| Float | 40.56M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.62 |
| P/TBV Ratio | 0.62 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 35.62, with a Debt / Equity ratio of 0.00.
| Current Ratio | 35.62 |
| Quick Ratio | 34.36 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -49.89% and return on invested capital (ROIC) is -34.84%.
| Return on Equity (ROE) | -49.89% |
| Return on Assets (ROA) | -32.76% |
| Return on Invested Capital (ROIC) | -34.84% |
| Return on Capital Employed (ROCE) | -31.37% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$5.35M |
| Employee Count | 5 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -52.60% in the last 52 weeks. The beta is 2.06, so CNTX's price volatility has been higher than the market average.
| Beta (5Y) | 2.06 |
| 52-Week Price Change | -52.60% |
| 50-Day Moving Average | 0.83 |
| 200-Day Moving Average | 1.66 |
| Relative Strength Index (RSI) | 38.62 |
| Average Volume (20 Days) | 73,062 |
Short Selling Information
The latest short interest is 2.37 million, so 2.65% of the outstanding shares have been sold short.
| Short Interest | 2.37M |
| Short Previous Month | 2.47M |
| Short % of Shares Out | 2.65% |
| Short % of Float | 5.86% |
| Short Ratio (days to cover) | 25.11 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -29.92M |
| Pretax Income | -18.57M |
| Net Income | -26.73M |
| EBITDA | -29.91M |
| EBIT | -29.92M |
| Earnings Per Share (EPS) | -$0.46 |
Full Income StatementBalance Sheet
The company has $94.43 million in cash and $219,380 in debt, giving a net cash position of $94.21 million or $1.05 per share.
| Cash & Cash Equivalents | 94.43M |
| Total Debt | 219,380 |
| Net Cash | 94.21M |
| Net Cash Per Share | $1.05 |
| Equity (Book Value) | 95.27M |
| Book Value Per Share | 1.06 |
| Working Capital | 95.15M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$14.56 million and capital expenditures -$7,316, giving a free cash flow of -$14.56 million.
| Operating Cash Flow | -14.56M |
| Capital Expenditures | -7,316 |
| Free Cash Flow | -14.56M |
| FCF Per Share | -$0.16 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |